iCAD, Inc. (NASDAQ:ICAD - Get Free Report)'s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.85 and traded as high as $3.54. iCAD shares last traded at $3.53, with a volume of 329,399 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded iCAD from a "hold" rating to a "sell" rating in a research note on Wednesday.
View Our Latest Stock Report on ICAD
iCAD Stock Down 8.0 %
The stock has a market cap of $88.11 million, a PE ratio of -25.54 and a beta of 1.47. The firm has a 50-day simple moving average of $2.37 and a 200-day simple moving average of $1.90.
Institutional Investors Weigh In On iCAD
Institutional investors have recently made changes to their positions in the stock. Summit Trail Advisors LLC purchased a new stake in shares of iCAD during the fourth quarter worth $214,000. waypoint wealth counsel increased its holdings in shares of iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock worth $26,000 after purchasing an additional 4,400 shares during the period. Essex LLC bought a new position in shares of iCAD in the third quarter worth $216,000. Wells Fargo & Company MN increased its holdings in shares of iCAD by 51.3% in the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock worth $72,000 after purchasing an additional 13,402 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new position in shares of iCAD in the fourth quarter worth $92,000. Hedge funds and other institutional investors own 24.61% of the company's stock.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Stories
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
